Sagimet Biosciences, Inc. Class A ( (SGMT) ) has issued an update.
On May 8, 2025, Sagimet Biosciences reported its first-quarter financial results and provided corporate updates, highlighting the initiation of a Phase 1 clinical trial in the second half of 2025 to evaluate the pharmacokinetics of a combination of denifanstat and resmetirom. This trial follows successful Phase 2b results and aims to explore the development of a combination product for MASH patients. The company also announced leadership changes and ongoing efforts to secure funding for further development of denifanstat as a monotherapy. Financially, Sagimet reported a net loss of $18.2 million for the quarter ended March 31, 2025, with cash and equivalents totaling $144.6 million.
Spark’s Take on SGMT Stock
According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.
Sagimet Biosciences’ overall score reflects substantial financial difficulties marked by persistent losses and reliance on external funding. While technical indicators show short-term bullish momentum, the lack of profitability and negative equity pose significant long-term risks. Valuation metrics further highlight the challenges in viewing this stock as an attractive investment.
To see Spark’s full report on SGMT stock, click here.
More about Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel fatty acid synthase (FASN) inhibitors targeting dysfunctional metabolic and fibrotic pathways. Their lead drug candidate, denifanstat, is an oral, once-daily pill designed for the treatment of metabolic dysfunction associated steatohepatitis (MASH). The company has successfully completed a Phase 2b clinical trial of denifanstat in MASH, with the drug receiving Breakthrough Therapy designation by the FDA.
Average Trading Volume: 563,416
Technical Sentiment Signal: Sell
Current Market Cap: $100.3M
For an in-depth examination of SGMT stock, go to TipRanks’ Stock Analysis page.